


Olaparib (AZD2281)

STUDY 19

In serous ovarian cancer

A Phase II randomized, double-blind, multicenter study to assess the efficacy of olaparib in the treatment of patients with platinum-sensitive serous ovarian cancer following treatment with two or more platinum containing regimens



Purpose: To determine the efficacy of olaparib compared to placebo in patients with platinum-sensitive serous ovarian cancer

Primary endpoint: Progression-free survival

Secondary endpoints: Overall response rate, duration of response, overall survival, quality of life, safety

Participating countries: Australia | Austria | Belgium | Canada | Czech Republic | Estonia | France | Germany | Israel | Netherlands | Poland | Romania | Russia | Spain | Ukraine | United Kingdom | United States

Olaparib is an investigational compound. This information is intended for potential clinical investigators and other interested physicians who may wish to enroll patients in clinical trials.

For more information,
please contact:

Cancer Study Locator service, sponsored by
AstraZeneca at 1-877-400-4656
Or via e-mail at: astrazeneca@emergingmed.com
To find available investigator site details, go to: www.clinicaltrials.gov

AstraZeneca 

AstraZeneca Pharmaceuticals, LP
Wilmington, Delaware
www.astrazeneca.com